Immunotherapy of multiple myeloma

Stem Cells
Y W Huang, Ellen S Vitetta

Abstract

In 1994, an estimated 12,700 new cases of multiple myeloma (MM) will be diagnosed in the USA and 9,800 patients will die from this disease. At present, a cure for MM has not been achieved with any chemotherapeutic regimen. Therefore, it is important to develop novel therapeutic approaches to treat this fatal disease. This review focuses on new concepts in the immunotherapy of MM. Thus far, interferons and anti-human interleukin (IL)-6 monoclonal anti-bodies (MAbs) have been used to treat patients with this disease. Bone marrow transplantation using autologous marrow purged with MAbs and complement, with anti-myeloma immunotoxins (ITs), or MAb-magnetic bead conjugates has been reported. Adoptive cellular therapy, in vivo with anti-CD3 and IL-2, as well as transplantation of purified autologous CD34+ peripheral blood stem cells, is now being evaluated in clinical trials. Anti-human IL-6 receptor (IL-6R) and anti-CD54 (ICAM-1) MAbs have shown promising results in the therapy of human myeloma cell lines in SCID mice, while an IL-6 antagonist protein, anti-gp130 MAbs, recombinant soluble gp130, anti-B7, anti-HLA-DR, and recombinant soluble CD16 also inhibit the growth of myeloma cell lines in vitro. These experimental therapeutic mo...Continue Reading

References

Nov 25, 1992·JAMA : the Journal of the American Medical Association·B BarlogieS Jagannath
Nov 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·T TagaT Kishimoto
Sep 1, 1992·Research in Immunology·B KleinR Bataille
Feb 1, 1992·Current Opinion in Oncology·F MandelliM Tribalto
Aug 1, 1992·European Journal of Immunology·H SuzukiT Kishimoto
Jan 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·S SuematsuT Kishimoto
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H LudwigH L Seewann
Apr 1, 1991·European Journal of Haematology·H Jernberg-WiklundK Nilsson
Aug 1, 1991·The Journal of Clinical Investigation·Y LevyJ C Brouet
Feb 1, 1989·British Journal of Haematology·E G Rhodes, M Flynn
Dec 1, 1988·Scandinavian Journal of Immunology·A C BloemR E Ballieux
Nov 1, 1983·Clinical Immunology and Immunopathology·M KamounJ A Hansen
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C A Uyl-de GrootF F Rutten
Aug 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P SonneveldK de Leeuw
Apr 1, 1993·Cancer Treatment Reviews·H M Lokhorst, A W Dekker
Jan 1, 1994·Journal of Clinical Apheresis·A Nademanee
Feb 1, 1995·British Journal of Haematology·D PeestR Bartl
Apr 1, 1994·British Journal of Haematology·A PalumboA Pileri
Jun 1, 1994·Critical Reviews in Oncology/hematology·C N Baxevanis, M Papamichail
Nov 1, 1993·Stem Cells·Y C Yang
Mar 16, 1994·Journal of the National Cancer Institute·R TaetleW Dalton
May 1, 1994·Clinical and Experimental Immunology·H HataK Takatsuki

❮ Previous
Next ❯

Citations

Oct 3, 1999·International Journal of Cancer. Journal International Du Cancer·J PostG C De Gast
Jul 31, 2001·International Journal of Cancer. Journal International Du Cancer·D HönemannR C Bargou
Mar 18, 1999·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·G A Siami, F S Siami
Nov 10, 2004·Journal of Immunotherapy·Joan E SmallshawEllen S Vitetta
Feb 24, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·H BouhlalN Haeffner Cavaillon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.